Asthma in ChildrenNCT03225534
Project 500 CHILD Study
An observational study of Asthma in Children and Allergy in Children, run by McMaster University.
Trial summary
This proposal relates to the testing of several specific hypotheses in a subset of 500 participants in the Canadian Healthy Infant Longitudinal Development (CHILD) Study. These 500 now have complete data from the time of recruitment (in pregnancy) to age 1 year. Read more about this study
- Who is it for?
- Ages 1 day to 18 monthsHealthy volunteers can take part
- Conditions the study is for
- Asthma in Children, Allergy in Children, Environmental Exposure
- How many people
- 500 participants
- Where
- No sites listed yet
- Study dates
- 31 Aug 2008to 31 Mar 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 18 months
- All sexes
- Healthy volunteers accepted
- Child
Study population: The 500 children in Project 500 will be representative of our full cohort. Study members have been recruited from a general population (i.e., not high-risk for asthma and allergy as are many cohorts) from recruitment bases in Vancouver, Edmonton, Winnipeg (including a rural site in Manitoba) and Toronto.
Who may be able to join
- Pregnant women aged 18 years and older (19 in Vancouver) 2. Residence in reasonable proximity to the delivery hospital 3. Able to read, write, and speak English 4. Willing to provide informed consent 5. Willing to consent to cord blood collection for the study 6. Planning to give birth at a designated recruitment centre participating hospital 7. Infants born at or after 35 weeks 8. Able to provide address and telephone number and names and telephone numbers of two alternate contact individuals
Who cannot join
- Children with major congenital abnormalities or respiratory distress syndrome (RDS)
- Expectation of moving away from a recruitment area within year 1
- Children of multiple births
- Children resulting from in vitro fertilization
- Children who will not spend at least 80% of nights in the index home
About this study
This proposal relates to the testing of several specific hypotheses in a subset of 500 participants in the Canadian Healthy Infant Longitudinal Development (CHILD) Study. These 500 now have complete data from the time of recruitment (in pregnancy) to age 1 year. The primary purpose of this proposal is to identify risk factors for early allergic outcomes and biomarkers that may predict future disease. These 500 infants will provide critical preliminary data, not only related to early outcomes, but also to inform analytical plans for the full CHILD cohort.
Read the detailed description
The objective of Project 500 is to carefully analyze a complete set of multiple clinical and environmental questionnaires and selected infant biological samples pertinent to early clinical outcomes (up to age 1 year). The primary clinical outcomes are recurrent episodes of wheezing and development of atopy by age 1 year. Atopy is defined by skin allergen responses. Secondary outcomes include atopic dermatitis or eczema, and reported food allergy. The investigators propose detailed exploration of patterns of clinical illnesses and will correlate these with analysis of multiple biomarkers to determine their predictive power.
There is good evidence from longitudinal epidemiological studies and from clinical trials that allergy is both a common precursor to childhood asthma and also a predictor of persistence of childhood asthma into adulthood. The "atopic march" is a well recognized phenomenon in which children develop atopic dermatitis and/or food allergy in early childhood, and then go on to have recurrent wheezing and persistent atopic asthma in later childhood and adulthood. The selection of specific hypotheses for examination in Project 500 reflects this phenomenon.
Four specific hypotheses will be tested in "Project 500":
- Maternal diet in pregnancy influences food sensitization in infancy; specifically avoidance of foods (e.g. peanuts) is associated with intolerance to that food. Research on diet and interventions to prevent atopic disease have focused on foods with anti-inflammatory properties (e.g. n-3 fatty acids), antioxidants (vitamin E and zinc), and vitamin D. Recent meta-analyses suggest beneficial effects for pre-natal vitamins A, D, and E, zinc, fruits and vegetables, and the Mediterranean diet. Nutrients may impact development of asthma through immune modulation or the child's intestinal microbiome. In spite of, or possibly because of, recommendations for early life avoidance of specific 'highly allergenic' foods including peanut in the 1990s from many national expert organizations (e.g. Canadian and British Pediatric Societies, American Academy of Pediatrics) there has been an explosion of food allergy, particularly to peanut in most high income countries (Miles and Buttriss, Nutrition Bulletin 2010). Intriguingly, studies have shown a very low prevalence of peanut allergy in Israel where peanut is commonly introduced in the first year of life compared with England where it is seldom introduced before the first birthday. This study accounted for a general heritable risk using children from a similar background (Ashkenazi Jewish) in both countries. (DuToit et al, JACI 2008). In the Danish National Birth Cohort maternal peanut (RR: 0.66; 95% CI: 0.44-0.98) and tree nut (RR: 0.83; 95% CI: 0.70-1.00) intake during pregnancy was associated with decreased risk of asthma in the child at 18 months of age. Intriguingly, there was no comment on the development of allergy in this cohort. The data being collected in the CHILD Study will allow the investigators to examine the link between maternal intake of specific foods such as peanut and the outcome of allergy to that food in the infant.
- Low serum 25-hydroxyvitamin D values in infancy are associated with development of early childhood wheezing. Most, but not all, studies have demonstrated a relationship of maternal vitamin D insufficiency with wheezing in pre-school children. A meta-analysis of four large cohort studies found that high maternal vitamin D intake during pregnancy was protective against wheeze in children. However, a recent publication from the ALSPAC cohort shows an association of increased wheeze with increased vitamin D levels. One issue may well be polymorphisms of the Vitamin D receptor in the mother (associated with vitamin D levels during pregnancy) and in their offspring during the few years of life. The data obtained in the CHILD Study will provide the opportunity to confirm or negate the associations between levels of vitamin D and wheezing syndromes in early childhood.
- Sensitization to cow's milk, egg or peanut, together or separately, at 1 year is a major risk factor for wheezing episodes in early infancy. Sensitization to foods has been associated with an increased risk for asthma (Rhodes et al, J Allergy Clin Immunol. 2001;108:720-5 and has recently been included in a modified Asthma Predictive Index (mAPI) (NEJM 2006;354:1985-97). The mAPI and an m2API have been validated in a small cohort as good predictors for persistent asthma at school age (Chang T et al, J Allergy Clin Immunol: In Practice 2013; 1:152-156). As yet unpublished data from a Canadian cohort show a substantial increased risk (OR 8-10) of persistent asthma in children with sensitization to a food in the first year of life (verbal communication, Becker A). The investigators will be able, using CHILD Study data, to examine these early life sensitization patterns in relation to the occurrence of wheezing episodes, and not only determine immediate relationships but also follow the children for several years to validate (or not) the Asthma Predictive Index.
- Exposures to oxidizing agents in the prenatal period and during the first 3 months of life influence the development of atopy and wheeze at 1 year. Infants raised in Canada spend a large majority of time indoors at home. Multiple indoor air exposures have been associated with wheeze and asthma, environmental tobacco smoke (ETS) being the most widely recognized. Oxides of nitrogen, associated with gas cooking and heating, are linked with worsening asthma. Innate immune inflammatory response can be activated by common indoor exposures, including trichloramines, aldehydes (e.g., formaldehyde) and other volatile organic compounds (VOCs) in home furnishings and cleaning products.
Recent studies suggest that early-life exposure to ambient air pollution may also contribute to the development of asthma, with traffic-related air pollution (TRAP) likely playing an important role. TRAP represents a complex mixture of pollutants (particulate matter, nitrogen oxides, carbon monoxide, organic compounds) in concentrations that are variable over short distances, but that also build-up over parts of the city contributing to a variable urban background. Respiratory health risks are generally highest among those living close to busy roads with significant truck traffic, but concentration variations across urban areas have also been associated with incident asthma. The effects of TRAP on airways disease likely also depend on poorly understood interactions with a range of endogenous or exogenous factors such as genetics, co-exposures such as allergens and environmental tobacco smoke, and psychosocial stress. The CHILD Study provides an opportunity to study TRAP in four major cities with highly variable and well-characterized concentrations, and to examine relationships between TRAP, indoor air contaminants, and development of wheeze and atopy in early childhood with the intent of following these children through childhood to determine asthma outcomes.
- Keywords
- Asthma, Allergy, Epidemiology, Environment, Exposures
- Medical subject headings
- Genetic Predisposition to Disease, Asthma, Hypersensitivity
What is being measured
The primary outcome is the main question the study is designed to answer.
Allergic sensitization at 1 year
Skin prick tests to food and inhalant allergies
Measured: March 2018
Secondary outcomes (2)
Early childhood wheeze
Parental report of childhood wheezing
Measured: Birth to one year
Atopic Dermatitis
Parental report of skin rashes
Measured: Birth to one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2017
- Study start31 Aug 2008
- Primary completion31 Oct 2012
- Study completion31 Mar 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Asthma in ChildrenStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (actual)
Sponsor and investigators
- Lead sponsor
- McMaster University
- Sponsor type
- University, hospital or other
- Collaborators
- Allergy, Genes and Environment Network (AllerGen) NCE, Canadian Institutes of Health Research (CIHR), St. Joseph's Healthcare Hamilton, University of Toronto, University of Manitoba, University of Alberta, University of British Columbia
- Responsible party
- Principal investigator, Malcolm Sears, McMaster University
- Investigators
- Padmaja Subbarao, MD, Study director, University of Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03225534
- Sponsor's protocol ID
- Project 500 ISS
- Status last verified
- Sep 2017
- First submitted
- 7 Jul 2017
- Last updated
- 25 Sep 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Takaro TK, Scott JA, Allen RW, Anand SS, Becker AB, Befus AD, Brauer M, Duncan J, Lefebvre DL, Lou W, Mandhane PJ, McLean KE, Miller G, Sbihi H, Shu H, Subbarao P, Turvey SE, Wheeler AJ, Zeng L, Sears MR, Brook JR; CHILD study investigators. The Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort study: assessment of environmental exposures. J Expo Sci Environ Epidemiol. 2015 Nov-Dec;25(6):580-92. doi: 10.1038/jes.2015.7. Epub 2015 Mar 25.
PubMed 25805254Moraes TJ, Lefebvre DL, Chooniedass R, Becker AB, Brook JR, Denburg J, HayGlass KT, Hegele RG, Kollmann TR, Macri J, Mandhane PJ, Scott JA, Subbarao P, Takaro TK, Turvey SE, Duncan JD, Sears MR, Befus AD; CHILD Study Investigators. The Canadian healthy infant longitudinal development birth cohort study: biological samples and biobanking. Paediatr Perinat Epidemiol. 2015 Jan;29(1):84-92. doi: 10.1111/ppe.12161. Epub 2014 Nov 18.
PubMed 25405552Subbarao P, Anand SS, Becker AB, Befus AD, Brauer M, Brook JR, Denburg JA, HayGlass KT, Kobor MS, Kollmann TR, Kozyrskyj AL, Lou WY, Mandhane PJ, Miller GE, Moraes TJ, Pare PD, Scott JA, Takaro TK, Turvey SE, Duncan JM, Lefebvre DL, Sears MR; CHILD Study investigators. The Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining developmental origins of allergy and asthma. Thorax. 2015 Oct;70(10):998-1000. doi: 10.1136/thoraxjnl-2015-207246. Epub 2015 Jun 11.
PubMed 26069286Azad MB, Robertson B, Atakora F, Becker AB, Subbarao P, Moraes TJ, Mandhane PJ, Turvey SE, Lefebvre DL, Sears MR, Bode L. Human Milk Oligosaccharide Concentrations Are Associated with Multiple Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices. J Nutr. 2018 Nov 1;148(11):1733-1742. doi: 10.1093/jn/nxy175.
PubMed 30247646
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Project 500 CHILD Study
- ClinicalTrials.gov ID
- NCT03225534
- Acronym / sponsor ID
- Project 500 ISS
- Keywords
- Asthma, Allergy, Epidemiology, Environment, Exposures
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (actual)
- Lead sponsor
- McMaster UniversityUniversity, hospital or other
- Collaborators
- Allergy, Genes and Environment Network (AllerGen) NCE, Canadian Institutes of Health Research (CIHR), St. Joseph's Healthcare Hamilton, University of Toronto, University of Manitoba, University of Alberta, University of British Columbia
- Study start
- 31 Aug 2008 (actual)
- Primary completion
- 31 Oct 2012 (actual)
- Study completion
- 31 Mar 2018 (estimated)
- First posted
- 21 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This proposal relates to the testing of several specific hypotheses in a subset of 500 participants in the Canadian Healthy Infant Longitudinal Development (CHILD) Study. These 500 now have complete data from the time of recruitment (in pregnancy) to age 1 year. The primary purpose of this proposal is to identify risk factors for early allergic outcomes and biomarkers that may predict future disease. These 500 infants will provide critical preliminary data, not only related to early outcomes, but also to inform analytical plans for the full CHILD cohort.
Detailed description
The objective of Project 500 is to carefully analyze a complete set of multiple clinical and environmental questionnaires and selected infant biological samples pertinent to early clinical outcomes (up to age 1 year). The primary clinical outcomes are recurrent episodes of wheezing and development of atopy by age 1 year. Atopy is defined by skin allergen responses. Secondary outcomes include atopic dermatitis or eczema, and reported food allergy. The investigators propose detailed exploration of patterns of clinical illnesses and will correlate these with analysis of multiple biomarkers to determine their predictive power.
There is good evidence from longitudinal epidemiological studies and from clinical trials that allergy is both a common precursor to childhood asthma and also a predictor of persistence of childhood asthma into adulthood. The "atopic march" is a well recognized phenomenon in which children develop atopic dermatitis and/or food allergy in early childhood, and then go on to have recurrent wheezing and persistent atopic asthma in later childhood and adulthood. The selection of specific hypotheses for examination in Project 500 reflects this phenomenon.
Four specific hypotheses will be tested in "Project 500":
- Maternal diet in pregnancy influences food sensitization in infancy; specifically avoidance of foods (e.g. peanuts) is associated with intolerance to that food. Research on diet and interventions to prevent atopic disease have focused on foods with anti-inflammatory properties (e.g. n-3 fatty acids), antioxidants (vitamin E and zinc), and vitamin D. Recent meta-analyses suggest beneficial effects for pre-natal vitamins A, D, and E, zinc, fruits and vegetables, and the Mediterranean diet. Nutrients may impact development of asthma through immune modulation or the child's intestinal microbiome. In spite of, or possibly because of, recommendations for early life avoidance of specific 'highly allergenic' foods including peanut in the 1990s from many national expert organizations (e.g. Canadian and British Pediatric Societies, American Academy of Pediatrics) there has been an explosion of food allergy, particularly to peanut in most high income countries (Miles and Buttriss, Nutrition Bulletin 2010). Intriguingly, studies have shown a very low prevalence of peanut allergy in Israel where peanut is commonly introduced in the first year of life compared with England where it is seldom introduced before the first birthday. This study accounted for a general heritable risk using children from a similar background (Ashkenazi Jewish) in both countries. (DuToit et al, JACI 2008). In the Danish National Birth Cohort maternal peanut (RR: 0.66; 95% CI: 0.44-0.98) and tree nut (RR: 0.83; 95% CI: 0.70-1.00) intake during pregnancy was associated with decreased risk of asthma in the child at 18 months of age. Intriguingly, there was no comment on the development of allergy in this cohort. The data being collected in the CHILD Study will allow the investigators to examine the link between maternal intake of specific foods such as peanut and the outcome of allergy to that food in the infant.
- Low serum 25-hydroxyvitamin D values in infancy are associated with development of early childhood wheezing. Most, but not all, studies have demonstrated a relationship of maternal vitamin D insufficiency with wheezing in pre-school children. A meta-analysis of four large cohort studies found that high maternal vitamin D intake during pregnancy was protective against wheeze in children. However, a recent publication from the ALSPAC cohort shows an association of increased wheeze with increased vitamin D levels. One issue may well be polymorphisms of the Vitamin D receptor in the mother (associated with vitamin D levels during pregnancy) and in their offspring during the few years of life. The data obtained in the CHILD Study will provide the opportunity to confirm or negate the associations between levels of vitamin D and wheezing syndromes in early childhood.
- Sensitization to cow's milk, egg or peanut, together or separately, at 1 year is a major risk factor for wheezing episodes in early infancy. Sensitization to foods has been associated with an increased risk for asthma (Rhodes et al, J Allergy Clin Immunol. 2001;108:720-5 and has recently been included in a modified Asthma Predictive Index (mAPI) (NEJM 2006;354:1985-97). The mAPI and an m2API have been validated in a small cohort as good predictors for persistent asthma at school age (Chang T et al, J Allergy Clin Immunol: In Practice 2013; 1:152-156). As yet unpublished data from a Canadian cohort show a substantial increased risk (OR 8-10) of persistent asthma in children with sensitization to a food in the first year of life (verbal communication, Becker A). The investigators will be able, using CHILD Study data, to examine these early life sensitization patterns in relation to the occurrence of wheezing episodes, and not only determine immediate relationships but also follow the children for several years to validate (or not) the Asthma Predictive Index.
- Exposures to oxidizing agents in the prenatal period and during the first 3 months of life influence the development of atopy and wheeze at 1 year. Infants raised in Canada spend a large majority of time indoors at home. Multiple indoor air exposures have been associated with wheeze and asthma, environmental tobacco smoke (ETS) being the most widely recognized. Oxides of nitrogen, associated with gas cooking and heating, are linked with worsening asthma. Innate immune inflammatory response can be activated by common indoor exposures, including trichloramines, aldehydes (e.g., formaldehyde) and other volatile organic compounds (VOCs) in home furnishings and cleaning products.
Recent studies suggest that early-life exposure to ambient air pollution may also contribute to the development of asthma, with traffic-related air pollution (TRAP) likely playing an important role. TRAP represents a complex mixture of pollutants (particulate matter, nitrogen oxides, carbon monoxide, organic compounds) in concentrations that are variable over short distances, but that also build-up over parts of the city contributing to a variable urban background. Respiratory health risks are generally highest among those living close to busy roads with significant truck traffic, but concentration variations across urban areas have also been associated with incident asthma. The effects of TRAP on airways disease likely also depend on poorly understood interactions with a range of endogenous or exogenous factors such as genetics, co-exposures such as allergens and environmental tobacco smoke, and psychosocial stress. The CHILD Study provides an opportunity to study TRAP in four major cities with highly variable and well-characterized concentrations, and to examine relationships between TRAP, indoor air contaminants, and development of wheeze and atopy in early childhood with the intent of following these children through childhood to determine asthma outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 1 day to 18 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- The 500 children in Project 500 will be representative of our full cohort. Study members have been recruited from a general population (i.e., not high-risk for asthma and allergy as are many cohorts) from recruitment bases in Vancouver, Edmonton, Winnipeg (including a rural site in Manitoba) and Toronto.
Key inclusion criteria (1 listed)
- Pregnant women aged 18 years and older (19 in Vancouver) 2. Residence in reasonable proximity to the delivery hospital 3. Able to read, write, and speak English 4. Willing to provide informed consent 5. Willing to consent to cord blood collection for the study 6. Planning to give birth at a designated recruitment centre participating hospital 7. Infants born at or after 35 weeks 8. Able to provide address and telephone number and names and telephone numbers of two alternate contact individuals
Key exclusion criteria (5 listed)
- Children with major congenital abnormalities or respiratory distress syndrome (RDS)
- Expectation of moving away from a recruitment area within year 1
- Children of multiple births
- Children resulting from in vitro fertilization
- Children who will not spend at least 80% of nights in the index home
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Allergic sensitization at 1 year
Time frame: March 2018
Skin prick tests to food and inhalant allergies
2 secondary outcomes
Early childhood wheeze
Time frame: Birth to one year
Atopic Dermatitis
Time frame: Birth to one year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2017.
- Background: PubMed 25805254Takaro TK, Scott JA, Allen RW, Anand SS, Becker AB, Befus AD, Brauer M, Duncan J, Lefebvre DL, Lou W, Mandhane PJ, McLean KE, Miller G, Sbihi H, Shu H, Subbarao P, Turvey SE, Wheeler AJ, Zeng L, Sears MR, Brook JR; CHILD study investigators. The Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort study: assessment of environmental exposures. J Expo Sci Environ Epidemiol. 2015 Nov-Dec;25(6):580-92. doi: 10.1038/jes.2015.7. Epub 2015 Mar 25.
- Background: PubMed 25405552Moraes TJ, Lefebvre DL, Chooniedass R, Becker AB, Brook JR, Denburg J, HayGlass KT, Hegele RG, Kollmann TR, Macri J, Mandhane PJ, Scott JA, Subbarao P, Takaro TK, Turvey SE, Duncan JD, Sears MR, Befus AD; CHILD Study Investigators. The Canadian healthy infant longitudinal development birth cohort study: biological samples and biobanking. Paediatr Perinat Epidemiol. 2015 Jan;29(1):84-92. doi: 10.1111/ppe.12161. Epub 2014 Nov 18.
- Background: PubMed 26069286Subbarao P, Anand SS, Becker AB, Befus AD, Brauer M, Brook JR, Denburg JA, HayGlass KT, Kobor MS, Kollmann TR, Kozyrskyj AL, Lou WY, Mandhane PJ, Miller GE, Moraes TJ, Pare PD, Scott JA, Takaro TK, Turvey SE, Duncan JM, Lefebvre DL, Sears MR; CHILD Study investigators. The Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining developmental origins of allergy and asthma. Thorax. 2015 Oct;70(10):998-1000. doi: 10.1136/thoraxjnl-2015-207246. Epub 2015 Jun 11.
- Derived from this study: PubMed 30247646Azad MB, Robertson B, Atakora F, Becker AB, Subbarao P, Moraes TJ, Mandhane PJ, Turvey SE, Lefebvre DL, Sears MR, Bode L. Human Milk Oligosaccharide Concentrations Are Associated with Multiple Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices. J Nutr. 2018 Nov 1;148(11):1733-1742. doi: 10.1093/jn/nxy175.
- Overview of the CHILD StudyLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Asthma in Children
Not yet recruitingObservational study
Prevelance of Broncial Asthma and Allergic Rhinitis in Children With Nephrotic Syndrim
Bronchial Asthma, Allergic Rhinitis
Active, not recruiting
Technology-Enhanced Asthma Care in Children at Clinic and Home Study
Asthma in Children, Chronic Diseases in Children
Active, not recruiting
AIRWEIGHS: Investigating Obesity as a Susceptibility Factor for Air Pollution in Childhood Asthma
Asthma
Not yet recruiting
Effects of Tele-rehabilitation-Guided Qigong on Children and Adolescents With Asthma
Asthma Childhood
Not yet recruiting
Effects of Respiratory Muscle Strength Training in Children With Asthma
Asthma (Diagnosis)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Padmaja Subbarao, MD study director
University of Toronto
Questions about this trial
What is this clinical trial studying?
An observational study of Asthma in Children and Allergy in Children, run by McMaster University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Allergic sensitization at 1 year (time frame: March 2018). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03225534, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2017.